Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 November 19, 2024
Rectify’s new lead candidate improves bile composition, reduces inflammation in mice with liver disease October 24, 2024
Rectify Pharma Announces Positive Functional Modulator RTY-694 as Development Candidate for Primary Sclerosing Cholangitis October 23, 2024
Rectify Pharmaceutical Announces Publication of Trends in Molecular Medicine Review Article Highlighting the Therapeutic Potential of the ABC Transporter Superfamily December 13, 2022
Startup Spotlight: Rectify is hoping it can mend broken ABC transporters, starting in the liver November 13, 2021
